Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: The NORDIC-VII study

Journal of Clinical Oncology

Volumn 30, Issue 15, 2012, Pages 1755-1762

  Tveit, Kjell Magne ^a,b   Guren, Tormod ^a   Glimelius, Bengt ^f,g   Pfeiffer, Per ^j   Sorbye, Halfdan ^c   Pyrhonen, Seppo ⁿ   Sigurdsson, Fridbjorn ^o   Kure, Elin ^a   Ikdahl, Tone ^a   Skovlund, Eva ^b   Fokstuen, Tone ^g   Hansen, Flemming ^k   Hofsli, Eva ^d   Birkemeyer, Elke ^e   Johnsson, Anders ^h   Starkhammar, Hans ⁱ   Yilmaz, Mette Karen ^l   Keldsen, Nina ^m   Erdal, Anne Berit ^a   Dajani, Olav ^a   Dahl, Olav ^c   Christoffersen, Thoralf ^b   more..

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e STAVANGER UNIVERSITY HOSPITAL   (Norway)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^g KAROLINSKA INSTITUTE   (Sweden)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^j ODENSE UNIVERSITY HOSPITAL   (Denmark)

^k AARHUS UNIVERSITY HOSPITAL   (Denmark)

^l AALBORG UNIVERSITY HOSPITAL   (Denmark)

^m HERNING HOSPITAL   (Denmark)

ⁿ TURKU UNIVERSITY HOSPITAL   (Finland)

^o LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; K RAS PROTEIN; OXALIPLATIN;

ADULT; AGED; ALLERGIC REACTION; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GENE MUTATION; HUMAN; HYPERSENSITIVITY; INFECTION; INTENTION TO TREAT ANALYSIS; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOTOR NEUROPATHY; MULTICENTER STUDY; NAIL DISEASE; NAUSEA; NEUTROPENIA; ONCOGENE K RAS; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RASH; SENSORY NEUROPATHY; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; MIDDLE AGED; MUTATION; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84861432557     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.38.0915     Document Type: Article

References (34)

1. Jemal A, Bray F, Center MM, et al: Global cancer statistics. CA Cancer J Clin 61:69-90, 2011
2. Cunningham D, Atkin W, Lenz HJ, et al: Colorectal cancer. Lancet 375:1030-1047, 2010
3. Tol J, Punt CJ: Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review. Clin Ther 32:437-453, 2010
4. Jorissen RN, Walker F, Pouliot N, et al: Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 284:31-53, 2003 (Pubitemid 36331965)
5. Holbro T, Civenni G, Hynes NE: The ErbB receptors and their role in cancer progression. Exp Cell Res 284:99-110, 2003 (Pubitemid 36331969)
6. Normanno N, De Luca A, Bianco C, et al: Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2-16, 2006 (Pubitemid 43199589)
7. Hynes NE, MacDonald G: ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21:177-184, 2009
8. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 358:1160-1174, 2008
9. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al: Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208, 2004 (Pubitemid 41079832)
10. Cunningham D, Humblet Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004 (Pubitemid 38944402)
11. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007 (Pubitemid 350106711)
12. Bokemeyer C, Bondarenko I, Hartmann JT, et al: Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: The OPUS study. Ann Oncol 22:1535-1546, 2011
13. Van Cutsem E, Köhne CH, Láng I, et al: Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011-2019, 2011
14. Maughan TS, Adams RA, Smith CG, et al: Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet 377:2103-2114, 2011
15. Amado RG, Wolf M, Peeters M, et al: Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626-1634, 2008
16. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
17. Peeters M, Price TJ, Cervantes A, et al: Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706-4713, 2010
18. Douillard JY, Siena S, Cassidy J, et al: Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 28:4697-4705, 2010
19. De Roock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 11:753-762, 2010
20. Di Nicolantonio F, Martini M, Molinari F, et al: Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712, 2008
21. Tol J, Nagtegaal ID, Punt CJ: BRAF mutation in metastatic colorectal cancer. N Engl J Med 361:98-99, 2009
22. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101:1308-1324, 2009
23. Sorbye H, Glimelius B, Berglund A, et al: Multicenter phase II study of Nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 22:31-38, 2004 (Pubitemid 41095111)
24. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
25. Hamfjord J, Stangeland AM, Skrede ML, et al: Wobble-enhanced ARMS method for detection of KRAS and BRAF mutations. Diagn Mol Pathol 20:158-165, 2011
26. Weisenberger DJ, Siegmund KD, Campan M, et al: CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet 38:787-793, 2006 (Pubitemid 43980599)
27. De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304:1812-1820, 2010
28. Scartozzi M, Bearzi I, Berardi R, et al: Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: Implications for treatment with EGFR-targeted monoclonal anti-bodies. J Clin Oncol 22:4772-4778, 2004
29. Prewett M, Deevi DS, Bassi R, et al: Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab. Clin Cancer Res 13:7432-7440, 2007
30. Balin-Gauthier D, Delord JP, Pillaire MJ, et al: Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. Br J Cancer 98:120-128, 2008
31. Dahan L, Sadok A, Formento JL, et al: Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol 158:610-620, 2009
32. Chibaudel B, Maindrault-Goebel F, Lledo G, et al: Can chemotherapy be discontinued in unresectable metastatic colorectal cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol 27:5727-5733, 2009
33. Adams RA, Meade AM, Seymour MT, et al: Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for firstline treatment of advanced colorectal cancer: Results of the randomised phase 3 MRC COIN trial. Lancet Oncol 12:642-653, 2011
34. Grothey A: EGFR antibodies in colorectal cancer: Where do they belong? J Clin Oncol 28:4668-4670, 2010